IL7 and acute lymphoblastic leukemia: In accordance with our hypothesis, we observed that in the absence of IL7, GSK-LSD1i impacted the growth of Zeb2Tg ETP-ALL within 48 hours and this effect was enhanced at high concentrations (Fig. 1A, B).